Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Recruiting · NCT03850418 · Registry updated 2026-02-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant | myeloid neoplasm | Recruiting | Phase 2 | 2026-02-24 | NCT03850418 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Henry Ford Health System | 77 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henry Ford Hospital | Detroit | United States | 326 |